Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the effects of CAP in PDAC are available to support the u...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0067330&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849470269538697216 |
|---|---|
| author | Aurélie Courtin Frances M Richards Tashinga E Bapiro Jo L Bramhall Albrecht Neesse Natalie Cook Ben-Fillippo Krippendorff David A Tuveson Duncan I Jodrell |
| author_facet | Aurélie Courtin Frances M Richards Tashinga E Bapiro Jo L Bramhall Albrecht Neesse Natalie Cook Ben-Fillippo Krippendorff David A Tuveson Duncan I Jodrell |
| author_sort | Aurélie Courtin |
| collection | DOAJ |
| description | Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the effects of CAP in PDAC are available to support the use of the GEMCAP combination in clinic. Therefore, we investigated the pharmacokinetics and the efficacy of CAP as a single agent first and then in combination with GEM to assess the utility of the GEMCAP therapy in clinic. Using a model of spontaneous PDAC occurring in Kras(G12D); p53(R172H); Pdx1-Cre (KPC) mice and subcutaneous allografts of a KPC PDAC-derived cell line (K8484), we showed that CAP achieved tumour concentrations (∼25 µM) of 5-FU in both models, as a single agent, and induced survival similar to GEM in KPC mice, suggesting similar efficacy. In vitro studies performed in K8484 cells as well as in human pancreatic cell lines showed an additive effect of the GEMCAP combination however, it increased toxicity in vivo and no benefit of a tolerable GEMCAP combination was identified in the allograft model when compared to GEM alone. Our work provides pre-clinical evidence of 5-FU delivery to tumours and anti-tumour efficacy following oral CAP administration that was similar to effects of GEM. Nevertheless, the GEMCAP combination does not improve the therapeutic index compared to GEM alone. These data suggest that CAP could be considered as an alternative to GEM in future, rationally designed, combination treatment strategies for advanced pancreatic cancer. |
| format | Article |
| id | doaj-art-e84923692d2b48e9bbd3ce4de3f87151 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-e84923692d2b48e9bbd3ce4de3f871512025-08-20T03:25:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6733010.1371/journal.pone.0067330Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.Aurélie CourtinFrances M RichardsTashinga E BapiroJo L BramhallAlbrecht NeesseNatalie CookBen-Fillippo KrippendorffDavid A TuvesonDuncan I JodrellCapecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the effects of CAP in PDAC are available to support the use of the GEMCAP combination in clinic. Therefore, we investigated the pharmacokinetics and the efficacy of CAP as a single agent first and then in combination with GEM to assess the utility of the GEMCAP therapy in clinic. Using a model of spontaneous PDAC occurring in Kras(G12D); p53(R172H); Pdx1-Cre (KPC) mice and subcutaneous allografts of a KPC PDAC-derived cell line (K8484), we showed that CAP achieved tumour concentrations (∼25 µM) of 5-FU in both models, as a single agent, and induced survival similar to GEM in KPC mice, suggesting similar efficacy. In vitro studies performed in K8484 cells as well as in human pancreatic cell lines showed an additive effect of the GEMCAP combination however, it increased toxicity in vivo and no benefit of a tolerable GEMCAP combination was identified in the allograft model when compared to GEM alone. Our work provides pre-clinical evidence of 5-FU delivery to tumours and anti-tumour efficacy following oral CAP administration that was similar to effects of GEM. Nevertheless, the GEMCAP combination does not improve the therapeutic index compared to GEM alone. These data suggest that CAP could be considered as an alternative to GEM in future, rationally designed, combination treatment strategies for advanced pancreatic cancer.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0067330&type=printable |
| spellingShingle | Aurélie Courtin Frances M Richards Tashinga E Bapiro Jo L Bramhall Albrecht Neesse Natalie Cook Ben-Fillippo Krippendorff David A Tuveson Duncan I Jodrell Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS ONE |
| title | Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. |
| title_full | Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. |
| title_fullStr | Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. |
| title_full_unstemmed | Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. |
| title_short | Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. |
| title_sort | anti tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0067330&type=printable |
| work_keys_str_mv | AT aureliecourtin antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT francesmrichards antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT tashingaebapiro antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT jolbramhall antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT albrechtneesse antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT nataliecook antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT benfillippokrippendorff antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT davidatuveson antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer AT duncanijodrell antitumourefficacyofcapecitabineinageneticallyengineeredmousemodelofpancreaticcancer |